Demographic data
| Women | Men | p Value | |
|---|---|---|---|
| Age | |||
| All | 70/14 | 67/14 | <0.0001 |
| CABG | 71/13 | 66/13 | <0.0001 |
| THR | 69/15 | 66/15 | <0.0001 |
| TKR | 71/12 | 70/12 | 0.0017 |
| Body weight (kg) | |||
| All | 74/19 | 84/18 | <0.0001 |
| CABG | 70/16 | 82/18 | <0.0001 |
| THR | 72/17 | 84/19 | <0.0001 |
| TKR | 78/20 | 87/18 | <0.0001 |
| Body height (m2) | |||
| All | 162/8 | 174/9 | <0.0001 |
| CABG | 160/9 | 173/8 | <0.0001 |
| THR | 162/9 | 175/10 | <0.0001 |
| TKR | 162/7 | 174/8 | <0.0001 |
| BSA (m2) | |||
| All | 1.79/0.23 | 1.99/0.23 | <0.0001 |
| CABG | 1.74/0.22 | 1.96/0.22 | <0.0001 |
| THR | 1.77/0.22 | 1.99/0.25 | <0.0001 |
| TKR | 1.82/0.23 | 2.02/0.24 | <0.0001 |
| ASA score | |||
| All | 2/1 | 3/1 | <0.0001 |
| CABG | 3/0 | 3/0 | 0.2332 |
| THR | 2/1 | 2/1 | 0.7003 |
| TKR | 2/1 | 2/1 | 0.9099 |
| EuroSCORE | |||
| CABG | 5/4 | 4/3 | <0.0001 |
| Preoperative anaemia (number yes (%)) | |||
| All | 629 (18.2) | 582 (19.0) | 0.3859 |
| CABG | 106 (30.3) | 270 (23.7) | 0.0126 |
| THR | 243 (17.1) | 173 (15.1) | 0.1780 |
| TKR | 280 (16.6) | 139 (17.9) | 0.4212 |
| Platelet inhibitors (preoperative) (number yes (%)) | |||
| All | 332 (9.6) | 730 (23.8) | <0.0001 |
| CABG | 159 (45.4) | 567 (49.7) | 0.1626 |
| THR | 70 (4.9) | 87 (7.6) | 0.0049 |
| TKR | 103 (6.1) | 76 (9.8) | 0.0011 |
| Regional anaesthesia (number yes (%)) | |||
| All | 1777 (51.3) | 1140 (37.2) | <0.0001 |
| THR | 777 (54.6) | 649 (56.6) | 0.2946 |
| TKR | 1000 (59.1) | 490 (63.0) | 0.0696 |
| Minimal invasive surgery (number yes (%)) | |||
| All | 59 (1.70) | 71 (2.32) | 0.0764 |
| CABG | 2 (0.57) | 14 (1.23) | 0.2977 |
| THR | 56 (3.93) | 56 (4.89) | 0.2390 |
| TKR | 1 (0.06) | 1 (0.13) | 0.5734 |
| Duration of surgery (min) | |||
| All | 80/45 | 105/122 | <0.0001 |
| CABG | 216/92 | 220/97 | 0.4573 |
| THR | 70/32 | 72/30 | 0.0012 |
| TKR | 84/39 | 90/46 | <0.0001 |
| Duration of extracorporeal circulation (min) | |||
| CABG | 88/39 | 90/44 | 0.458 |
| Use of aprotinin or tranexamic acid* (number yes (%)) | |||
| CABG | 336 (96) | 1103 (96.7) | 0.5503 |
| Use of cell saver (number yes (%)) | |||
| All | 1694 (48.9) | 1478 (48.2) | 0.5904 |
| CABG | 152 (43.4) | 504 (44.2) | 0.8064 |
| THR | 750 (52.7) | 589 (51.4) | 0.5210 |
| TKR | 792 (46.8) | 385 (49.5) | 0.2207 |
| Length of stay (days) | |||
| All | 12/4 | 11/4 | <0.0001 |
| CABG | 10/6 | 10/5 | 0.1753 |
| THR | 12/4 | 11/3 | <0.0001 |
| TKR | 12/3 | 12/4 | 0.0015 |
Bold values indicate p Values <0.05.
Values are presented as median/IQR for non-normally distributed variables, or number (%) for categorical variables.
The percentages are calculated based on the total applicable population for each variable.
Presented p values correspond to Mann-Whitney U test, or χ2 test, respectively.
*Aprotinin was used in the first study and tranexamic acid was used in the second study only.
ASA, American Society of Anaesthesiology; CABG, coronary artery bypass graft; THR, total hip replacement; TKR, total knee replacement.